Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
1.680
-0.010 (-0.59%)
At close: Apr 1, 2026, 4:00 PM EDT
1.700
+0.020 (1.19%)
Pre-market: Apr 2, 2026, 5:54 AM EDT
Aldeyra Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Aldeyra Therapeutics stock have a consensus rating of "Buy" and an average price target of $5.50, which forecasts a 227.38% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $9.00.
Price Target: $5.50 (+227.38%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Aldeyra Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $10 → $2 | Strong Buy → Hold | Downgrades | $10 → $2 | +19.05% | Mar 18, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +435.71% | Nov 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +495.24% | May 19, 2025 |
| BTIG | BTIG | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +435.71% | Apr 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +495.24% | Apr 4, 2025 |
Financial Forecast
Revenue This Year
63.35M
Revenue Next Year
69.51M
from 63.35M
Increased by 9.72%
EPS This Year
-0.50
from -0.56
EPS Next Year
0.16
from -0.50
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 86.0M | 71.6M | |||
| Avg | 63.3M | 69.5M | |||
| Low | 41.5M | 66.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 13.0% | |||
| Avg | - | 9.7% | |||
| Low | - | 5.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.37 | 0.98 | |||
| Avg | -0.50 | 0.16 | |||
| Low | -0.61 | -0.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.